Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

• Published in: Respiratory research Vol. 18; no. 1; pp. 109 - 9
• Main Authors: Ra, Seung Won, Sze, Marc A., Lee, Eun Chong, Tam, Sheena, Oh, Yeni, Fishbane, Nick, Criner, Gerard J., Woodruff, Prescott G., Lazarus, Stephen C., Albert, Richard, Connett, John E., Han, Meilan K., Martinez, Fernando J., Aaron, Shawn D., Reed, Robert M., Man, S. F. Paul, Sin, Don D.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30.05.2017; BioMed Central; BMC
• Subjects: Age; Aged; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Antibiotics; Antibodies, Bacterial - blood; Assaying; Azithromycin; Azithromycin - adverse effects; Azithromycin - therapeutic use; Biomarkers; Biomarkers - blood; Blood; C-Reactive Protein - metabolism; Care and treatment; Chronic infection; Chronic obstructive lung disease; Chronic obstructive pulmonary disease; Complications and side effects; COPD; Cytokines; Disease Progression; Disease-Free Survival; Dosage and administration; Drug therapy; Dyspnea; Exacerbation; Female; Hazards; Health aspects; Health hazards; Health risk assessment; Helicobacter infections; Helicobacter Infections - blood; Helicobacter Infections - diagnosis; Helicobacter Infections - drug therapy; Helicobacter Infections - microbiology; Helicobacter pylori; Helicobacter pylori - drug effects; Helicobacter pylori - immunology; Humans; Infections; Inflammation; Kaplan-Meier Estimate; Lung - drug effects; Lung - microbiology; Lung - physiopathology; Lung diseases; Male; Middle Aged; Minority & ethnic groups; Obstructive lung disease; Patients; Plasma; Prevention; Prognosis; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - microbiology; Pulmonary Disease, Chronic Obstructive - physiopathology; Quality; Randomization; Receptors, Tumor Necrosis Factor, Type II - blood; Respiration; Respiratory function; Risk Factors; Serologic Tests; Sex; Smoking; Studies; Survival; Time Factors; TNF inhibitors; Treatment Outcome; Tumor necrosis factor; Tumor necrosis factor-TNF; Ulcers; Canada; Exacerbation; Helicobacter pylori; Azithromycin; COPD

Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the eff...